Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis

Eiichi Ogawa, Norihiro Furusyo, Makoto Nakamuta, Eiji Kajiwara, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Takeaki Satoh, Koichi Azuma, Akira Kawano, Yuichi Tanabe, Kazuhiro Kotoh, Shinji Shimoda, Tomohiko Akahoshi, Yoshihiko Maehara, Jun Hayashi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background and Aim: Thrombocytopenia (TCP) of chronic hepatitis C patients with cirrhosis has a negative impact on the management of interferon-based treatment. The aim of this study is to evaluate the efficacy and safety of telaprevir-based triple therapy for patients who have undergone splenectomy (Spx). Methods: This prospective, multicenter study consisted of 80 patients, including 32 Spx and 48 non-Spx/TCP (platelet count: 60-99×109/L) patients with advanced fibrosis infected with hepatitis C virus genotype 1b. All received 12 weeks of telaprevir in combination with 24 weeks of pegylated interferon (PEG-IFN) α2b and ribavirin. Results: The sustained virological response (SVR) rate of the Spx group (75.0%) was significantly higher than that of the non-Spx/TCP group (52.1%) (P<0.05). Under favorable conditions such as treatment-naïve/prior relapse and interleukin-28B (IL28B) TT allele (rs8099917), the SVR rates of the Spx group were significantly higher than those of the non-Spx/moderate TCP (60-79×109/L) groups (91.3% vs 50.0% and 93.8% vs 37.5%, respectively; both P<0.05). Adequate PEG-IFNα2b adherence was associated with SVR. However, the percentage of patients who achieved 80% adherence to PEG-IFNα2b in the non-Spx/moderate TCP (42.9%) group was significantly lower than that of the Spx (79.3%) and non-Spx/mild TCP (80-99×109/L) (80.0%) groups. Treatment discontinuation due to adverse effects and the development of bacterial infection did not differ between the Spx and non-Spx/TCP groups. Conclusion: The increase of platelet count after Spx contributed to treatment success, especially for moderate to severe TCP patients who are treatment-naïve/prior relapse or IL28B TT allele.

Original languageEnglish
Pages (from-to)1728-1735
Number of pages8
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume29
Issue number9
DOIs
Publication statusPublished - Sep 2014

Fingerprint

Splenectomy
Chronic Hepatitis C
Thrombocytopenia
Fibrosis
Safety
Interleukins
Therapeutics
Platelet Count
Interferons
Alleles
Recurrence
telaprevir
Ribavirin
Bacterial Infections
Hepacivirus
Multicenter Studies
Genotype
Prospective Studies

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis. / Ogawa, Eiichi; Furusyo, Norihiro; Nakamuta, Makoto; Kajiwara, Eiji; Nomura, Hideyuki; Dohmen, Kazufumi; Takahashi, Kazuhiro; Satoh, Takeaki; Azuma, Koichi; Kawano, Akira; Tanabe, Yuichi; Kotoh, Kazuhiro; Shimoda, Shinji; Akahoshi, Tomohiko; Maehara, Yoshihiko; Hayashi, Jun.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 29, No. 9, 09.2014, p. 1728-1735.

Research output: Contribution to journalArticle

Ogawa, E, Furusyo, N, Nakamuta, M, Kajiwara, E, Nomura, H, Dohmen, K, Takahashi, K, Satoh, T, Azuma, K, Kawano, A, Tanabe, Y, Kotoh, K, Shimoda, S, Akahoshi, T, Maehara, Y & Hayashi, J 2014, 'Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis', Journal of Gastroenterology and Hepatology (Australia), vol. 29, no. 9, pp. 1728-1735. https://doi.org/10.1111/jgh.12619
Ogawa, Eiichi ; Furusyo, Norihiro ; Nakamuta, Makoto ; Kajiwara, Eiji ; Nomura, Hideyuki ; Dohmen, Kazufumi ; Takahashi, Kazuhiro ; Satoh, Takeaki ; Azuma, Koichi ; Kawano, Akira ; Tanabe, Yuichi ; Kotoh, Kazuhiro ; Shimoda, Shinji ; Akahoshi, Tomohiko ; Maehara, Yoshihiko ; Hayashi, Jun. / Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis. In: Journal of Gastroenterology and Hepatology (Australia). 2014 ; Vol. 29, No. 9. pp. 1728-1735.
@article{5b71763722934a2bb0dd500bad15a396,
title = "Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis",
abstract = "Background and Aim: Thrombocytopenia (TCP) of chronic hepatitis C patients with cirrhosis has a negative impact on the management of interferon-based treatment. The aim of this study is to evaluate the efficacy and safety of telaprevir-based triple therapy for patients who have undergone splenectomy (Spx). Methods: This prospective, multicenter study consisted of 80 patients, including 32 Spx and 48 non-Spx/TCP (platelet count: 60-99×109/L) patients with advanced fibrosis infected with hepatitis C virus genotype 1b. All received 12 weeks of telaprevir in combination with 24 weeks of pegylated interferon (PEG-IFN) α2b and ribavirin. Results: The sustained virological response (SVR) rate of the Spx group (75.0{\%}) was significantly higher than that of the non-Spx/TCP group (52.1{\%}) (P<0.05). Under favorable conditions such as treatment-na{\"i}ve/prior relapse and interleukin-28B (IL28B) TT allele (rs8099917), the SVR rates of the Spx group were significantly higher than those of the non-Spx/moderate TCP (60-79×109/L) groups (91.3{\%} vs 50.0{\%} and 93.8{\%} vs 37.5{\%}, respectively; both P<0.05). Adequate PEG-IFNα2b adherence was associated with SVR. However, the percentage of patients who achieved 80{\%} adherence to PEG-IFNα2b in the non-Spx/moderate TCP (42.9{\%}) group was significantly lower than that of the Spx (79.3{\%}) and non-Spx/mild TCP (80-99×109/L) (80.0{\%}) groups. Treatment discontinuation due to adverse effects and the development of bacterial infection did not differ between the Spx and non-Spx/TCP groups. Conclusion: The increase of platelet count after Spx contributed to treatment success, especially for moderate to severe TCP patients who are treatment-na{\"i}ve/prior relapse or IL28B TT allele.",
author = "Eiichi Ogawa and Norihiro Furusyo and Makoto Nakamuta and Eiji Kajiwara and Hideyuki Nomura and Kazufumi Dohmen and Kazuhiro Takahashi and Takeaki Satoh and Koichi Azuma and Akira Kawano and Yuichi Tanabe and Kazuhiro Kotoh and Shinji Shimoda and Tomohiko Akahoshi and Yoshihiko Maehara and Jun Hayashi",
year = "2014",
month = "9",
doi = "10.1111/jgh.12619",
language = "English",
volume = "29",
pages = "1728--1735",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis

AU - Ogawa, Eiichi

AU - Furusyo, Norihiro

AU - Nakamuta, Makoto

AU - Kajiwara, Eiji

AU - Nomura, Hideyuki

AU - Dohmen, Kazufumi

AU - Takahashi, Kazuhiro

AU - Satoh, Takeaki

AU - Azuma, Koichi

AU - Kawano, Akira

AU - Tanabe, Yuichi

AU - Kotoh, Kazuhiro

AU - Shimoda, Shinji

AU - Akahoshi, Tomohiko

AU - Maehara, Yoshihiko

AU - Hayashi, Jun

PY - 2014/9

Y1 - 2014/9

N2 - Background and Aim: Thrombocytopenia (TCP) of chronic hepatitis C patients with cirrhosis has a negative impact on the management of interferon-based treatment. The aim of this study is to evaluate the efficacy and safety of telaprevir-based triple therapy for patients who have undergone splenectomy (Spx). Methods: This prospective, multicenter study consisted of 80 patients, including 32 Spx and 48 non-Spx/TCP (platelet count: 60-99×109/L) patients with advanced fibrosis infected with hepatitis C virus genotype 1b. All received 12 weeks of telaprevir in combination with 24 weeks of pegylated interferon (PEG-IFN) α2b and ribavirin. Results: The sustained virological response (SVR) rate of the Spx group (75.0%) was significantly higher than that of the non-Spx/TCP group (52.1%) (P<0.05). Under favorable conditions such as treatment-naïve/prior relapse and interleukin-28B (IL28B) TT allele (rs8099917), the SVR rates of the Spx group were significantly higher than those of the non-Spx/moderate TCP (60-79×109/L) groups (91.3% vs 50.0% and 93.8% vs 37.5%, respectively; both P<0.05). Adequate PEG-IFNα2b adherence was associated with SVR. However, the percentage of patients who achieved 80% adherence to PEG-IFNα2b in the non-Spx/moderate TCP (42.9%) group was significantly lower than that of the Spx (79.3%) and non-Spx/mild TCP (80-99×109/L) (80.0%) groups. Treatment discontinuation due to adverse effects and the development of bacterial infection did not differ between the Spx and non-Spx/TCP groups. Conclusion: The increase of platelet count after Spx contributed to treatment success, especially for moderate to severe TCP patients who are treatment-naïve/prior relapse or IL28B TT allele.

AB - Background and Aim: Thrombocytopenia (TCP) of chronic hepatitis C patients with cirrhosis has a negative impact on the management of interferon-based treatment. The aim of this study is to evaluate the efficacy and safety of telaprevir-based triple therapy for patients who have undergone splenectomy (Spx). Methods: This prospective, multicenter study consisted of 80 patients, including 32 Spx and 48 non-Spx/TCP (platelet count: 60-99×109/L) patients with advanced fibrosis infected with hepatitis C virus genotype 1b. All received 12 weeks of telaprevir in combination with 24 weeks of pegylated interferon (PEG-IFN) α2b and ribavirin. Results: The sustained virological response (SVR) rate of the Spx group (75.0%) was significantly higher than that of the non-Spx/TCP group (52.1%) (P<0.05). Under favorable conditions such as treatment-naïve/prior relapse and interleukin-28B (IL28B) TT allele (rs8099917), the SVR rates of the Spx group were significantly higher than those of the non-Spx/moderate TCP (60-79×109/L) groups (91.3% vs 50.0% and 93.8% vs 37.5%, respectively; both P<0.05). Adequate PEG-IFNα2b adherence was associated with SVR. However, the percentage of patients who achieved 80% adherence to PEG-IFNα2b in the non-Spx/moderate TCP (42.9%) group was significantly lower than that of the Spx (79.3%) and non-Spx/mild TCP (80-99×109/L) (80.0%) groups. Treatment discontinuation due to adverse effects and the development of bacterial infection did not differ between the Spx and non-Spx/TCP groups. Conclusion: The increase of platelet count after Spx contributed to treatment success, especially for moderate to severe TCP patients who are treatment-naïve/prior relapse or IL28B TT allele.

UR - http://www.scopus.com/inward/record.url?scp=84906519675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906519675&partnerID=8YFLogxK

U2 - 10.1111/jgh.12619

DO - 10.1111/jgh.12619

M3 - Article

C2 - 24731162

AN - SCOPUS:84906519675

VL - 29

SP - 1728

EP - 1735

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 9

ER -